B & T Capital Management DBA Alpha Capital Management decreased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.2% during the second quarter, Holdings Channel reports. The institutional investor owned 12,546 shares of the medical instruments supplier’s stock after selling 281 shares during the period. Becton, Dickinson and Company comprises 1.2% of B & T Capital Management DBA Alpha Capital Management’s portfolio, making the stock its 20th largest position. B & T Capital Management DBA Alpha Capital Management’s holdings in Becton, Dickinson and Company were worth $2,448,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the stock. Triangle Securities Wealth Management raised its stake in shares of Becton, Dickinson and Company by 0.6% in the first quarter. Triangle Securities Wealth Management now owns 3,896 shares of the medical instruments supplier’s stock valued at $715,000 after buying an additional 25 shares during the period. Atalanta Sosnoff Capital LLC purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $27,395,000. Private Asset Management Inc. purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $956,000. Toth Financial Advisory Corp raised its stake in shares of Becton, Dickinson and Company by 2.2% in the first quarter. Toth Financial Advisory Corp now owns 23,478 shares of the medical instruments supplier’s stock valued at $4,307,000 after buying an additional 509 shares during the period. Finally, Macquarie Group Ltd. raised its stake in shares of Becton, Dickinson and Company by 16.0% in the fourth quarter. Macquarie Group Ltd. now owns 67,709 shares of the medical instruments supplier’s stock valued at $11,209,000 after buying an additional 9,340 shares during the period. 75.42% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company (BDX) opened at 200.78 on Monday. The stock has a market cap of $42.83 billion, a price-to-earnings ratio of 33.35 and a beta of 1.05. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $200.92. The firm’s 50-day moving average price is $190.01 and its 200-day moving average price is $181.27.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Tuesday, May 2nd. The medical instruments supplier reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.23 by $0.07. Becton, Dickinson and Company had a return on equity of 25.37% and a net margin of 10.67%. The firm had revenue of $2.97 billion during the quarter, compared to analysts’ expectations of $2.92 billion. During the same quarter last year, the business posted $2.18 earnings per share. The firm’s revenue was down 3.2% on a year-over-year basis. On average, equities analysts predict that Becton, Dickinson and Company will post $9.45 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, June 30th. Investors of record on Friday, June 9th were given a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a dividend yield of 1.46%. The ex-dividend date was Wednesday, June 7th. Becton, Dickinson and Company’s dividend payout ratio is currently 48.26%.

TRADEMARK VIOLATION NOTICE: “B & T Capital Management DBA Alpha Capital Management Cuts Position in Becton, Dickinson and Company (BDX)” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.watchlistnews.com/b-t-capital-management-dba-alpha-capital-management-cuts-position-in-becton-dickinson-and-company-bdx/1445092.html.

BDX has been the subject of several recent research reports. Zacks Investment Research raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating and set a $206.00 price objective for the company in a report on Tuesday, April 11th. Jefferies Group LLC reissued a “buy” rating and issued a $200.00 price objective on shares of Becton, Dickinson and Company in a report on Wednesday, March 29th. Royal Bank Of Canada reissued a “hold” rating and issued a $177.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday, April 13th. Evercore ISI raised Becton, Dickinson and Company from an “in-line” rating to an “outperform” rating and lifted their price objective for the stock from $186.00 to $200.00 in a report on Monday, April 24th. Finally, Cowen and Company reissued an “outperform” rating and issued a $230.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and Company in a report on Monday, July 10th. One analyst has rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $190.58.

In related news, VP Jeffrey S. Sherman sold 28,765 shares of the stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the completion of the sale, the vice president now owns 70,821 shares in the company, valued at $13,171,289.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.